Ovid Therapeutics Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Ovid Therapeutics Inc. (OVID) reported Cash and Cash Equivalents, Period Increase (Decrease) of $10.87 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-07.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-07
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$7.24M.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $18.11M.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $5.98M.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $7.98M.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$50.64M, a 243.91% decline from fiscal 2017.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $35.19M.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$18.00M, a 127.66% decline from fiscal 2015.
- Ovid Therapeutics Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $65.10M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$7.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $10.87M 10-Q · filed 2019-08-07 | $16.85M derived: sum of 3 quarters · filed 2019-08-07 | $24.83M derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | $18.11M 10-Q · filed 2019-05-07 | $24.09M derived: sum of 2 quarters · filed 2019-05-07 | $32.06M derived: sum of 3 quarters · filed 2019-05-07 | $25.40M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $13.95M derived: sum of 2 quarters · filed 2019-03-07 | $7.29M derived: sum of 3 quarters · filed 2019-08-07 | -$50.64M 10-K · filed 2019-03-07 |
| 2018-09-30 | $7.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.31M derived: sum of 2 quarters · filed 2019-08-07 | -$56.61M 10-Q · filed 2018-11-08 | -$65.53M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-06-30 | -$6.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$64.59M 10-Q · filed 2019-08-07 | -$73.51M derived: sum of 3 quarters · filed 2019-08-07 | -$83.58M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$57.92M 10-Q · filed 2019-05-07 | -$66.84M derived: sum of 2 quarters · filed 2019-05-07 | -$76.91M derived: sum of 3 quarters · filed 2019-05-07 | -$15.02M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | -$8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$18.99M derived: sum of 2 quarters · filed 2019-03-07 | $42.90M derived: sum of 3 quarters · filed 2019-03-07 | $35.19M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$10.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $51.82M derived: sum of 2 quarters · filed 2018-11-08 | $44.10M 10-Q · filed 2018-11-08 | $38.29M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $61.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $54.18M 10-Q · filed 2018-08-09 | $48.36M derived: sum of 3 quarters · filed 2018-08-09 | $43.66M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | -$7.71M 10-Q · filed 2018-05-08 | -$13.53M derived: sum of 2 quarters · filed 2018-05-08 | -$18.23M derived: sum of 3 quarters · filed 2018-05-08 | -$21.81M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | -$5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | -$10.52M derived: sum of 2 quarters · filed 2018-03-29 | -$14.10M derived: sum of 3 quarters · filed 2018-03-29 | -$18.00M 10-K · filed 2018-03-29 |
| 2016-09-30 | -$4.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$8.28M derived: sum of 2 quarters · filed 2017-11-09 | -$12.19M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | -$3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$7.49M 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$3.91M 10-Q · filed 2017-06-13 | |||
| 2015-12-31 | $65.10M 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |